Doyle Mittie: insider trades.
Doyle Mittie reported 11 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($160K), across 1 company.
- Transactions
- 11
- Purchases (P)
- 0
- Sales (S)
- 5
- Companies
- 1
- Name as filed
- Doyle Mittie
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | Officer · Chief Medical Officer | 11 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-28 | Avalo Therapeutics, Inc. | M | 679 | $8.04 | 52,455 | Form 4 |
| 2026-08-28 | Avalo Therapeutics, Inc. | S | 679 | $20 | 51,776 | Form 4 |
| 2026-08-17 | Avalo Therapeutics, Inc. | S | 1,000 | $20 | 51,776 | Form 4 |
| 2026-08-17 | Avalo Therapeutics, Inc. | M | 1,000 | $12.65 | 52,776 | Form 4 |
| 2026-08-10 | Avalo Therapeutics, Inc. | M | 679 | $8.04 | 52,455 | Form 4 |
| 2026-08-10 | Avalo Therapeutics, Inc. | S | 679 | $20 | 51,776 | Form 4 |
| 2026-07-27 | Avalo Therapeutics, Inc. | S | 1,000 | $20 | 51,776 | Form 4 |
| 2026-07-27 | Avalo Therapeutics, Inc. | M | 1,000 | $12.65 | 52,776 | Form 4 |
| 2026-06-30 | Avalo Therapeutics, Inc. | M | 2,875 | $12.65 | 54,651 | Form 4 |
| 2026-06-30 | Avalo Therapeutics, Inc. | M | 1,779 | $8.04 | 56,430 | Form 4 |
| 2026-06-30 | Avalo Therapeutics, Inc. | S | 4,654 | $20 | 51,776 | Form 4 |
Questions
What stock did Doyle Mittie buy or sell?
Doyle Mittie reported 11 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($160K), across 1 company.
Is Doyle Mittie the same person as other filers with this name?
This page covers SEC CIK 1918845 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/doyle-mittie-1918845.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.